Key result
Novel 4′-[(benzimidazol-1-yl)methyl]biphenyl-2-sulphonamides were designed as dual angiotensin II and endothelin A receptor antagonists and evaluated using a 3D pharmacophore model.
Answers are grounded in this paper and cite their sources.
This study describes the design of novel 4′-[(benzimidazol-1-yl)methyl]biphenyl-2-sulphonamides as potential dual angiotensin II and endothelin A receptor antagonists.
A series of novel 4′-[(benzimidazol-1-yl)methyl]biphenyl-2-sulphonamides was designed, and their molecular model simulation fitting to a new HipHop 3D pharmacophore model was examined.
No takes yet. Share an insight, caveat, or question.
Hao et al. (2015) studied this question. Novel 4′-[(benzimidazol-1-yl)methyl]biphenyl-2-sulphonamides were designed as dual angiotensin II and endothelin A receptor antagonists and evaluated using a 3D pharmacophore model.
Synapse has enriched 10 related papers. Consider them for comparative context: